SCHEMBL4460274

SCHEMBL4460274

COC(=O)c1ccc(OCc2ccccc2)cc1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.57
P2RY14 Q15391 1/20 0.52
PPARG P37231 1/20 0.52
GSTP1 P09211 2/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
ALDH1A1 P00352 2/20 0.49
TOP1 P11387 1/20 0.49
BACE1 P56817 1/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
MAOA P21397 1/20 0.48
MCL1 Q07820 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3912364 0.89 MAOB (0.56) MAOBNPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6771894 0.88 GPR132 (0.50)
SCHEMBL11593773 0.86 P2RY14 (0.60) MAOBP2RY14GSTP1SMN1; SMN2HPGD
SCHEMBL3962253 0.85 MAOB (0.61) MAOBNPC1RAB9ASMN1; SMN2LMNA
Hydrochloric Acid SCHEMBL9222328 0.85 P2RY14 (0.59) MAOBP2RY14GSTP1SMN1; SMN2HPGD
SCHEMBL629952 0.85 MAOB (0.74) MAOBNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL22692220 0.83 MAOB (0.59) MAOBNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL22873361 0.83 MAOB (0.59) MAOBNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL7881166 0.83 MAOB (0.59) MAOBNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6775841 0.83 KDM4E (0.62) SMN1; SMN2LMNAHPGDALDH1A1BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629366-B2 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2009-12-08 US disclosed
US-20060100252-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2006-05-11 US disclosed
US-7037938-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2006-05-02 US disclosed
US-20040006143-A1 For therapy of urinary incontinence FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-01-08 US disclosed
US-6204293-B1 INHIBITING POST-TRANSLATIONAL MODIFICATION OF THE ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE, PROTEIN GERANYLGERANYLTRANSFERASE, OR BOTH UNIVERSITY OF PITTSBURGH 2001-03-20 US disclosed
WO-1998050031-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100252-A1 Aminoalcohol derivatives H1-0, CHRM2, CHRM1 MAOB 2016/4885P2RY14 1906/4885PPARG 994/4885
US-20040006143-A1 For therapy of urinary incontinence H1-0, HRH2, H1-2 MAOB 1897/4885P2RY14 2662/4885PPARG 2013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.